zaragozic-acid-c and squalestatin-1

The zaragozic acids (ZAs), a family of fungal metabolites containing a novel 4,6,7-trihydroxy-2,8-dioxobicyclo[3.2.1]octane-3,4,5-tricarboxylic acid core, were discovered independently by two separate groups screening natural product sources to discover inhibitors of squalene synthase. This family of compounds all contain the same core but differ in their 1-alkyl and their 6-acyl side chains. Production of the ZAs is distributed over an extensive taxonomic range of Ascomycotina or their anamorphic states. The zaragozic acids are very potent inhibitors of squalene synthase that inhibit cholesterol synthesis and lower plasma cholesterol levels in primates. They also inhibit fungal ergosterol synthesis and are potent fungicidal compounds. The biosynthesis of the zaragozic acids appears to proceed through alkyl citrate intermediates and new members of the family have been produced through directed biosynthesis. These potent natural product based inhibitors of squalene synthase have potential to be developed either as cholesterol lowering agents and/or as antifungal agents.

Topics: Animals; Anticholesteremic Agents; Antifungal Agents; Ascomycota; Bridged Bicyclo Compounds, Heterocyclic; Drug Evaluation, Preclinical; Drug Industry; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Tricarboxylic Acids

Topics: Alkylation; Biological Products; Bridged Bicyclo Compounds, Heterocyclic; Catalysis; Molecular Structure; Tricarboxylic Acids

A carbonyl ylide cycloaddition approach to the squalene synthase inhibitors zaragozic acids A and C is described. The carbonyl ylide precursor 8 was synthesized starting from di-tert-butyl D-tartrate (47) via an eleven-step sequence involving the regioselective reduction of the mono-MPM (MPM=4-methoxybenzyl) ether 48 with LiBH4 and the diastereoselective addition of sodium tert-butyl diazoacetate to alpha-keto ester 10. The reaction of alpha-diazo ester 8 with 3-butyn-2-one (40) in the presence of a catalytic amount of [Rh2(OAc)4] gave the desired cycloadduct 59 as a single diastereomer. The dihydroxylation of enone 59 followed by sequential transformations permitted the construction of the fully functionalized 2,8-dioxabicyclo[3.2.1]octane core 5. Alkene 79 derived from 5 serves as a common precursor to zaragozic acids A (1) and C (2), since the elongation of the C1 alkyl side chain can be attained by olefin cross-metathesis, especially under the influence of Blechert's catalyst (85).

Topics: Alkenes; Bridged Bicyclo Compounds, Heterocyclic; Catalysis; Cross-Linking Reagents; Cyclization; Enzyme Inhibitors; Models, Chemical; Organometallic Compounds; Stereoisomerism; Tartrates; Tricarboxylic Acids

Topics: Anticholesteremic Agents; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Tricarboxylic Acids

Three closely related fungal metabolites, zaragozic acids A, B, and C, that are potent inhibitors of squalene synthase have been isolated and characterized. Zaragozic acids A, B, and C were produced from an unidentified sterile fungal culture, Sporormiella intermedia, and Leptodontium elatius, respectively. The structures of the zaragozic acids and their trimethyl esters were determined by a combination of physical and chemical techniques. The zaragozic acids are characterized by a novel 2,8-dioxobicyclo[3.2.1]octane-4,6,7- trihydroxyl-3,4,5-tricarboxylic acid core and differ from each other in the structures of the 6-acyl and 1-alkyl side chains. They were found to be potent competitive inhibitors of rat liver squalene synthase with apparent Ki values of 78 pM, 29 pM, and 45 pM, respectively. They inhibited cholesterol synthesis in Hep G2 cells, and zaragozic acid A was an inhibitor of acute hepatic cholesterol synthesis in the mouse (50% inhibitory dose of 200 micrograms/kg of body weight). Inhibition of squalene synthase in cells and in vivo was accompanied by an accumulation of label from [3H]mevalonate into farnesyl diphosphate, farnesol, and organic acids. These data indicate that the zaragozic acids are a previously unreported class of therapeutic agents with potential for the treatment of hypercholesterolemia.

Topics: Animals; Ascomycota; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Chromatography, High Pressure Liquid; Farnesyl-Diphosphate Farnesyltransferase; Female; Fermentation; Humans; Kinetics; Lipids; Liver; Mice; Mitosporic Fungi; Molecular Structure; Tricarboxylic Acids; Tumor Cells, Cultured